The short version
- The National Health Service is piloting a rapid genetic test that reduces brain tumour diagnosis time from weeks to hours.
- Surgeons can now receive molecular classification results while patients are still on the operating table, influencing surgical strategy.
- The initiative involves five specialist centers in England and aims to expand further, addressing the high mortality rate of primary brain tumours.
The National Health Service in England has begun piloting a rapid genomic test designed to drastically reduce the time required for accurate brain tumour diagnosis. Previously, determining the specific type of tumour could take up to eight weeks, leaving patients and families in prolonged uncertainty. The new technology compresses this timeline to approximately two hours, allowing medical teams to identify the genetic makeup of the growth while the patient is still undergoing surgery.
This development addresses a critical bottleneck in neuro-oncology care. There are roughly 150 distinct types of brain tumours, ranging from slow-growing lesions to aggressive cancers, each requiring different therapeutic approaches. Traditional diagnostic methods rely on molecular and genetic analysis that typically requires sending tissue samples away for extended processing. The delay often postpones the start of essential treatments such as radiotherapy and chemotherapy.
The pilot program utilizes a sequencing machine developed by Oxford Nanopore, which is about the size of a shoebox. Tissue samples taken from the tumour are prepared and loaded into the device. Specialized software, created in partnership between the University of Nottingham and hospital clinicians, analyzes the DNA as molecules pass through tiny nanopores. This process reveals the tumour’s unique genomic fingerprint with high speed and precision.
The clinical implications of receiving results during surgery are significant for surgical decision-making. For certain tumour types that are potentially curable, surgeons may opt for more radical procedures to remove every visible trace of the cancer. Conversely, if the test identifies a highly aggressive type that is beyond surgical cure, doctors might adopt a more cautious approach to minimize damage to healthy brain tissue and reduce post-operative risks.
Steve Palmer, a 55-year-old resident of Nottingham, experienced the benefits of this technology firsthand after collapsing at a gym. During his operation at Queens Medical Centre, part of Nottingham University Hospitals NHS Trust, surgeons received confirmation that he had a grade 4 glioblastoma while he was still on the table. Palmer noted that the rapid diagnosis eliminated weeks of anxiety and allowed him to immediately focus on the next phase of treatment and recovery.
Medical professionals involved in the trial have expressed strong support for the technology. Consultant neurosurgeon Stuart Smith described the ability to obtain full diagnostic information during the operation as almost magical. Dr Simon Paine, a consultant neuropathologist at the same trust, contrasted the new method with traditional microscopic examination, which he characterized as somewhat speculative compared to the comprehensive molecular classification provided by the nanopore system.
The initial pilot involves five specialist centers across England: Nottingham University Hospitals NHS Foundation Trust, University Hospitals Birmingham NHS Foundation Trust, Great Ormond Street Hospital NHS Foundation Trust, King's College Hospital, and Newcastle Hospitals NHS Foundation Trust. This effort builds upon earlier projects already underway in Nottingham and Birmingham. Plans are in place to extend the program to additional sites in Bristol, Oxford, Leeds, and Manchester.
Primary brain tumours remain a significant health challenge in the UK, with more than 12,000 diagnoses annually. It is the leading cause of cancer death among children and adults under the age of 40. NHS medical director Prof Frankie Swords emphasized that quick access to accurate diagnosis can feel like a race against time for patients. The rapid test offers a potential pathway to faster treatment initiation and earlier access to clinical trials, marking a substantial advancement in patient care.
Prof Dame Sue Hill, chief scientific officer for England and senior responsible officer for genomics in the NHS, highlighted the development as another world-leading achievement for NHS genomics. By transforming diagnostic timelines from weeks to days or even hours, the technology aims to improve outcomes for patients who have previously faced agonizing waits for answers. The expansion of this pilot represents a strategic shift toward more responsive and precise neurological care.
While the early results are promising, the broader implementation will depend on the success of the current pilot phases. The integration of rapid genomic sequencing into routine surgical workflows requires coordination between operating theatres, pathology labs, and genetic analysis teams. If the trial demonstrates consistent reliability and clinical benefit, it could set a new standard for brain tumour management in the UK and potentially influence practices globally.
Sources behind this briefing
Go to the original reporting
- BBC News↗From weeks to hours - the rapid new test transforming brain tumour diagnosis
